Biotech | October 14, 2021
Sputnik Light has 70 % efficacy against infection with Delta: Gamaleya analysis
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
The batch will be distributed in India through a partner of RDIF and Panacea Biotec - Dr. Reddy's Laboratories
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
This is the first of its kind vaccine for Covid 19 to get the go-ahead
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
AstraZeneca, Sinopharm and Moderna were part of the study
Subscribe To Our Newsletter & Stay Updated
